Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (58)

IV-01Stefaan Rossenu

Population Pharmacokinetics of MK-3475, a human Anti-PD-1 Monoclonal Antibody in patients with progressive locally advanced or metastatic carcinoma, melanoma, and non-small cell lung carcinoma

Thursday 15:15-16:40

IV-02Tarjinder Sahota

Interactive population PK/PD model simulations in R

Thursday 15:15-16:40

IV-03Maria Luisa Sardu

Steady-state equivalence of drug- and biomarker driven models in tumor growth experiments

Thursday 15:15-16:40

IV-04Andre Schäftlein

Population modeling of the relationship between the pharmacokinetics of the oral thrombin inhibitor dabigatran etexilate and coagulation biomarkers in patients with non-valvular atrial fibrillation from the RE-LY trial

Thursday 15:15-16:40

IV-05Emilie Schindler

PKPD-Modeling of individual lesion maximal standardized uptake value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib

Thursday 15:15-16:40

IV-06Jan-Frederik Schlender

Development of a whole-body PBPK approach to assess the pharmacokinetics of xenobiotics in elderly individuals

Thursday 15:15-16:40

IV-07Stephan Schmidt

Evaluation of changes in oral drug absorption in preterm neonates for BCS class I and II compounds

Thursday 15:15-16:40

IV-08

Are insulin measurements needed in glucose provocation studies? : Comparison of study power using Monte-Carlo Mapped Power (MCMP) method

Thursday 15:15-16:40

IV-09Shinji Shimizu

PBPK modeling of CNS distribution for risperidone and its active metabolite, paliperidone

Thursday 15:15-16:40

IV-10Kwang-Hee Shin

A population pharmacokinetic/pharmacodynamic approaches of a peglyated granulocyte-colony stimulating factor (G-CSF) in healthy Korean

Thursday 15:15-16:40

IV-11Satoshi Shoji

Evaluation of information of prior relative to current data in analysis with prior

Thursday 15:15-16:40

IV-12Nelleke Snelder

A new model-based approach to compare toxicity of a series of compounds based on their categorical toxicity scores

Thursday 15:15-16:40

IV-13Kabir Soeny

A Novel Algorithm for Optimizing Dose Regimens and Fixed Dose Combination Ratios

Thursday 15:15-16:40

IV-14Mijeong Son

Population Pharmacokinetic-Pharmacodynamic modeling of Olemsartan in Healthy Korean Volunteers

Thursday 15:15-16:40

IV-15Konstantina Soulele

A population pharmacokinetic study of fluticasone/salmeterol in healthy subjects using two different dry powder inhalers

Thursday 15:15-16:40

IV-16Christine Staatz

A survey of intravenous tobramycin monitoring and dosage adjustment practice in cystic fibrosis patients in Australia and the United Kingdom

Thursday 15:15-16:40

IV-17Elisabet Størset

Evaluation of dosing strategies to achieve targeted tacrolimus exposure after adult kidney transplantation

Thursday 15:15-16:40

IV-18

Evaluating the clinical influence of UGT2B15 genotype on the pharmacodynamic response of the PPAR agonist, sipoglitazar

Thursday 15:15-16:40

IV-19Mark Stroh

Meta-analysis of Published Efficacy and Safety Data for Docetaxel in Second-Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer

Thursday 15:15-16:40

IV-20

Design evaluation using a bootstrapped Monte Carlo variance-covariance matrix.

Thursday 15:15-16:40

IV-21Kim Stuyckens

Modelling and simulation approach to optimize the pharmacological activity during a Phase 1 study of JNJ-42756493, a selective and potent FGFR 1, 2 ,3 and 4 inhibitor.

Thursday 15:15-16:40

IV-22Siddharth Sukumaran

Development of a Mechanism-based pharmacokinetic model for MMAE conjugated ADCs

Thursday 15:15-16:40

IV-23Ahmed Suleiman

A survival modeling analysis evaluating the use of positron emission tomography with [(18)F]-fluorodeoxyglucose for predicting the prognosis in advanced non-small cell lung cancer patients first-treated with erlotinib

Thursday 15:15-16:40

IV-24Amit Taneja

Development of a mechanism-based pharmacokinetic-pharmacodynamic model of prolactin response following administration of D2 antagonists in rats

Thursday 15:15-16:40

IV-25Paulo Teixeira

Population Pharmacokinetic Model of Valproic Acid in Adult Patients: an Update

Thursday 15:15-16:40

IV-26Nadia Terranova

An energy based model able to describe the effect of anticancer drugs on tumor growth and host body weight

Thursday 15:15-16:40

IV-27Adrien Tessier

Contribution of nonlinear mixed effects models and penalised regression approaches in pharmacogenetic population studies

Thursday 15:15-16:40

IV-29

A semi-mechanistic model to describe the bidirectional interaction between oncolytic reovirus and in vitro tumor growth of U87-glioblastoma cells

Thursday 15:15-16:40

IV-30Iñaki F. Trocóniz

Population pharmacokinetic/pharmacodynamic modelling of the analgesic and pupillometry effects of axomadol and its O-demethyl metabolite in healthy subjects

Thursday 15:15-16:40

IV-31Sebastian Ueckert

Accelerating Monte-Carlo Power Studies through Parametric Power Estimation

Thursday 15:15-16:40

IV-32Pavan Vajjah

Exposure-response relationship of certolizumab pegol in psoriatic arthritis patients and comparison of ACR 20/50/70 response rates in the two dosage regimens

Thursday 15:15-16:40

IV-33Elodie Valade

Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics

Thursday 15:15-16:40

IV-34Pyry Välitalo

Evaluation of gentamicin and tobramycin dosing guidelines for neonates; towards model-based dosing

Thursday 15:15-16:40

IV-35Sven van Dijkman

A PKPD Hidden Markov Model for Lamotrigine in all age groups

Thursday 15:15-16:40

IV-36Coen van Hasselt

Development of an integrated model-based framework to support clinical development of antibiotics

Thursday 15:15-16:40

IV-37Eline van Maanen

Integrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model. Application to the APP pathway in CMP rhesus monkeys.

Thursday 15:15-16:40

IV-38Anne van Rongen

Population pharmacokinetics of a single intravenous dose of midazolam in obese, overweight and non-obese adolescents

Thursday 15:15-16:40

IV-39Rob van Wijk

Challenges in the evaluation of the preclinical dosing rationale for tuberculosis treatment

Thursday 15:15-16:40

IV-40Marc Vandemeulebroecke

Identifying neuropsychological domains with high information on early signs of cognitive decline: An application of Item Response Theory in the Basel Study on the Elderly

Thursday 15:15-16:40

IV-41

Analysis of Sleep Changes Induced by Citalopram: A Population Approach

Thursday 15:15-16:40

IV-42Swantje Völler

Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer: Results of the EPOC-MS-001 Study

Thursday 15:15-16:40

IV-43Chenguang Wang

Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults

Thursday 15:15-16:40

IV-44Shaonan Wang

Exposure-response analysis of Axomadol in patients suffering from hip and/or knee-joint osteoarthritis pain

Thursday 15:15-16:40

IV-45Franziska Weber

Evaluation of candidate drugs to induce the redundant gene ABCD2 as an alternative treatment option for X-linked adrenoleukodystrophy

Thursday 15:15-16:40

IV-46

Nonlinear mixed-effects modelling of the oral absorption of mavoglurant following administration of an immediate- and a modified-release formulation in healthy subjects

Thursday 15:15-16:40

IV-47Sebastian Wicha

Adaptive optimal design for the concentration tiers in time-kill curve experiments.

Thursday 15:15-16:40

IV-48Pawel Wiczling

PK/PD of propofol and fentanyl in patients undergoing abdominal aortic surgery – the influence of cardiac output and drug interactions

Thursday 15:15-16:40

IV-49Wenyuan Xiong

PK/PD modeling of the c-Met inhibitor MSC2156119J to establish the recommended Phase II dose

Thursday 15:15-16:40

IV-50Shuying Yang

Probability of Success with Exposure Response Modelling and Clinical Trial Simulation as a Tool to Support Decision Making

Thursday 15:15-16:40

IV-51Huixin Yu

Integrated mechanism-based pharmacokinetic model for sunitinib and its active metabolite

Thursday 15:15-16:40

IV-52Hinojal Zazo Gómez

PK/PD modelling and simulation of stavudine nanoparticles in HIV patients

Thursday 15:15-16:40

IV-53Stefan Zeiser

Whole-Body PBPK Modeling of Tacrolimus in Healthy Volunteers

Thursday 15:15-16:40

IV-54Jianping Zhang

Pharmacokinetics of eltrombopag in patients with hepatic impairment

Thursday 15:15-16:40

IV-55Liping Zhang

A Mechanistic Modeling Approach Characterizing the Interaction of Pharmacokinetics and Pharmacodynamics of a Monoclonal Antibody and the Supply/Synthesis of its target in Cynomolgus Monkey

Thursday 15:15-16:40

IV-56Simon Zhou

Uncertainty and key factors in assessing drug effect in cell-based and xenograft tumor models in rodents

Thursday 15:15-16:40

IV-57Li Zhu

Population Pharmacokinetic/Pharmacodynamic Models for the Heart Rate Effects of BMS-820836, a Triple Monoamine Reuptake Inhibitor, in a Thorough QT Study

Thursday 15:15-16:40

IV-58Morris Muliaditan

Population Pharmacokinetic Meta-Analysis of the Antiretroviral Agent Lamivudine in HIV-Infected Children

Thursday 15:15-16:40

IV-59Oscar Della Pasqua

Population Pharmacokinetic Meta-Analysis of the Antiretroviral Agent Abacavir in HIV-Infected Children

Thursday 15:15-16:40